David Y. Liu - 16 Nov 2022 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief R&D Strategy Officer
Signature
/s/ Asif Ali, Attorney-in-Fact for David Y. Liu
Issuer symbol
PTGX
Transactions as of
16 Nov 2022
Net transactions value
+$231,802
Form type
4
Filing time
17 Nov 2022, 17:24:16 UTC
Previous filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $11,977 +13,767 +21% $0.8700* 80,878 16 Nov 2022 Direct F1
transaction PTGX Common Stock Options Exercise $18,382 +9,726 +12% $1.89* 90,604 16 Nov 2022 Direct
transaction PTGX Common Stock Options Exercise $11,338 +5,999 +6.6% $1.89* 96,603 16 Nov 2022 Direct
transaction PTGX Common Stock Options Exercise $41,361 +35,656 +37% $1.16* 132,259 16 Nov 2022 Direct
transaction PTGX Common Stock Options Exercise $148,744 +35,331 +27% $4.21 167,590 16 Nov 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -13,767 -100% $0.000000* 0 16 Nov 2022 Common Stock 13,767 $0.8700 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -9,726 -100% $0.000000* 0 16 Nov 2022 Common Stock 9,726 $1.89 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -5,999 -100% $0.000000* 0 16 Nov 2022 Common Stock 5,999 $1.89 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -35,656 -100% $0.000000* 0 16 Nov 2022 Common Stock 35,656 $1.16 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -35,331 -100% $0.000000* 0 16 Nov 2022 Common Stock 35,331 $4.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022.
F2 The stock option is vested in full.

Remarks:

Exhibit 24 - Power of Attorney